Bispecific κλ bodies targeting CD47 and membrane proximal epitopes on MSLN afford enhanced efficacy in vitro and in vivo.
Light Chain Bioscience is leveraging its proprietary bispecific antibody format to advance immune therapies in oncology and beyond.
Light Chain Bioscience successfully completes Factor VIII mimetic bispecific antibody discovery for Takeda.
NovImmune SA is excited to be launching today the all new company website and branding.
